文献速递脊柱关节炎

高选择性酪氨酸激酶2抑制剂zasocitinib(TAK-279)改善活动性银屑病关节炎患者的结局:一项随机2b期研究

Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study.
PubMed 文献 · Ann Rheum Dis · 2025-07-04

这项2b期随机、多中心、双盲、安慰剂对照、多剂量研究纳入290例活动性银屑病关节炎患者,每日一次口服zasocitinib 30 mg、15 mg、5 mg或安慰剂治疗12周。第12周时,30 mg和15 mg组的ACR20应答率均显著高于安慰剂组(54.2%和53.3% vs 29.2%)。大多数不良事件为轻中度,在高剂量组更常见,未发现新的安全信号。

要点

  • 第12周ACR20应答率:30 mg组54.2%(P = .002)、15 mg组53.3%(P = .002)vs 安慰剂组29.2%。
  • 第12周ACR50应答率:30 mg组26.4%(名义P = .009)、15 mg组26.7%(名义P = .005)vs 安慰剂组9.7%。
  • 30 mg组第12周ACR70、PASI 75和MDA应答率分别为13.9%、45.7%和29.2%,均高于安慰剂组。

核心结论

  • 在活动性银屑病关节炎患者中,zasocitinib 30 mg和15 mg在核心领域均显示疗效,且未发现新的安全信号。
  • 这些发现将在正在进行的更大规模、更长疗程的研究中加以确认。

研究设计与样本

  • 2b期、随机、多中心、双盲、安慰剂对照、多剂量研究。
  • 纳入年龄≥18岁、银屑病关节炎症状持续≥6个月的患者,按1:1:1:1随机接受zasocitinib 30 mg、15 mg、5 mg或安慰剂每日一次治疗12周,并设4周安全性随访。
  • 共290例患者接受治疗,平均(SD)年龄49.9(11.6)岁,女性占57.2%。

主要发现

  • 第12周ACR20应答率:30 mg组54.2%(P = .002)、15 mg组53.3%(P = .002),均显著高于安慰剂组29.2%。
  • 第12周ACR50应答率:30 mg组26.4%(名义P = .009)、15 mg组26.7%(名义P = .005),数值上高于安慰剂组9.7%。
  • 第12周30 mg组vs安慰剂组:ACR70应答率13.9% vs 5.6%(名义P = .158),PASI 75应答率45.7% vs 15.4%(名义P = .002),MDA 29.2% vs 12.5%(名义P = .014)。
  • 大多数不良事件为轻中度,在高剂量组更常见;未发现新的安全信号或明确的剂量依赖性实验室参数变化。

关键数值与推荐

  • 主要终点为第12周ACR20应答率。
  • 次要疗效终点包括第12周ACR50应答率、ACR70应答率、基线体表面积≥3%者的PASI 75应答率及MDA。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文自述本研究样本量小且疗程有限。
  • 原文指出这些发现将在正在进行的更大规模、更长疗程的研究中加以确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the efficacy, safety, and tolerability of the investigational, oral, allosteric, highly selective, and potent tyrosine kinase 2 inhibitor zasocitinib (TAK-279) in patients with active psoriatic arthritis (PsA). METHODS: In this phase 2b, randomised, multicentre, double-blind, placebo-controlled, multiple-dose study, patients (≥18 years, with PsA symptoms for ≥6 months) received 30 mg, 15 mg, or 5 mg zasocitinib or placebo (1:1:1:1) once daily for 12 weeks, with a 4-week safety follow-up. The primary endpoint was American College of Rheumatology (ACR)20 response at week 12. Secondary efficacy endpoints included ACR50 response, ACR70 response, Psoriasis Area and Severity Index (PASI) 75 response among those with ≥3% body surface area at baseline and minimal disease activity (MDA) at week 12. RESULTS: Overall, 290 patients (mean [SD] age, 49.9 [11.6] years; 57.2% female) received treatment. At week 12, 30 mg or 15 mg zasocitinib treatment resulted in significantly higher ACR20 responses (54.2%; P = .002 and 53.3%; P = .002, respectively) than placebo (29.2%). A numerically higher number of ACR50 responses were achieved at week 12 with 30 mg (26.4%; nominal P = .009) or 15 mg (26.7%; nominal P = .005) zasocitinib than placebo (9.7%). In addition, 30 mg zasocitinib demonstrated a numerically higher number of ACR70 responses (13.9% versus 5.6%, respectively; nominal P = .158), PASI 75 responses (45.7% versus 15.4%, respectively; nominal P = .002), and MDA (29.2% versus 12.5%, respectively; nominal P = .014) at week 12 versus placebo. In this small study of limited duration, most adverse events were mild/moderate and were more frequently observed in the higher dose group. In this small sample size, no new safety signals or clear dose-dependent laboratory parameter changes were identified. CONCLUSIONS: Here, 30 mg and 15 mg zasocitinib demonstrated efficacy across core domains in patients with active PsA with no new safety signals. These findings will be confirmed in ongoing larger studies of longer duration.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kivitz A, Baraliakos X, Muensterman ET, et al. Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study. Ann Rheum Dis. 2025. PMID: 40615297. doi:10.1016/j.ard.2025.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。